| ★ | Chat-GPT and more – how AI will revolutionize medicine and the management of rare diseases | | 71 | — | |
| 7 | Hydroxychloroquine in connective tissue diseases: benefits and controversial aspects | | 1.8K | — | 67 |
| 1 | IgG4-related disease (IgG4-RD): update on diagnosis and treatments in 2025 | | 1.3K | — | 73 |
| 8 | Diagnosis and management of peripheral neurological manifestations in Sjögren’s disease | | 748 | — | 66 |
| 17 | CAR-T Therapy in Systemic Lupus Erythematosus (SLE): Explained to the Patient | | 441 | — | 63 |
| 5 | What is the added value of triple therapy in lupus nephritis? | | 438 | — | 68 |
| 14 | Update on B cell targeting therapies in IgG4-related disease | | 375 | — | 64 |
| 11 | Autoantibodies and clinical phenotypes in Idiopathic Inflammatory Myopathies (IIMs) | | 286 | — | 65 |
| 4 | Treatment of systemic sclerosis-associated interstitial lung disease: where do we stand in 2025? | | 285 | — | 69 |
| 19 | Microvascular Involvement in Antiphospholipid Syndrome (APS) | | 264 | — | 63 |
| 12 | Pulmonary Function Tests: A Practical Guide for Rheumatologists | | 253 | — | 65 |
| 15 | Autonomous GIS: The Next-Generation AI-Powered GIS | International Society for Digital Earth @isde_digitalearth | 246 | — | 64 |
| 20 | Exercise in adult idiopathic inflammatory myopathies (IIMs) | | 188 | — | 63 |
| 10 | Imaging in Relapsing Polychondritis (RP) | | 171 | — | 65 |
| 13 | The Path to Better Treatments: A Patient-Friendly Guide to Sjögren’s Clinical Trials | | 171 | — | 65 |
| 3 | Vaccination in undifferentiated connective tissue disease (UCTD) | | 103 | — | 70 |
| 6 | Osteoporosis in rare and complex connective tissue diseases | | 96 | — | 67 |
| 9 | Unmet Needs in Childhood-Onset Sjögren's Disease – Patient and Clinician Perspectives | | 82 | — | 65 |
| 18 | Multidisciplinary diagnosis and team treatment in Idiopathic Inflammatory Myopathies | | 64 | — | 63 |
| 2 | Screening and treatment of systemic sclerosis-associated PAH: where do we stand in 2024? | | 53 | — | 71 |
| 16 | “Doctor, can you ask me…?” for connective tissue diseases patients | | 46 | — | 63 |